Effect of Pravastatin on malondialdehyde-modified low-density lipoprotein levels and coronary plaque regression as determined by 3-dimensional intravascular ultrasound
Effect of Pravastatin on malondialdehyde-modified low-density lipoprotein levels and coronary plaque regression as determined by 3-dimensional intravascular ultrasound
复制标题
DOI：
10.1016/j.amjcard.2005.05.069
复制
发表时间：
2005-10-15
影响因子：
2.8
通讯作者：
Kushiro, T
中科院分区：
文献类型：
--
作者：
Tani, S;Watanabe, I;Kushiro, T
我们假设，致动脉粥样硬化的丙二醛修饰的低密度脂蛋白（MOA-LDL）水平的降低，这可能会拮抗动脉粥样硬化保护性高密度脂蛋白胆固醇的作用，导致冠状动脉斑块消退。本研究旨在探讨普伐他汀对血清MDA-LDL水平及冠状动脉粥样硬化的影响。在一项为期6个月的前瞻性研究中，75例稳定性冠状动脉疾病患者被随机分配到普伐他汀治疗组（n = 52）或对照组（n = 13）。通过三维血管内超声对匹配的冠状动脉段进行容积分析。普伐他汀治疗6个月导致冠状动脉斑块体积减少（14.4%，p < 0.0001），血清MDA-LDL水平相应降低（12.7%，p <0.0001）。在普伐他汀治疗组中，斑块体积的变化百分比与MDA-LDL和高密度脂蛋白胆固醇水平的变化相关（r分别为0.52和-0.55，p < 0.0001），但与任何其他脂质水平的变化无关。多变量回归分析显示，MDA-LDL水平降低是斑块消退的独立预测因子，高密度脂蛋白胆固醇升高也是如此。这些结果提示，普伐他汀诱导的MDA-LDL水平的降低可能作为冠状动脉粥样硬化消退的新标志。(c)2005年爱思唯尔公司All rights reserved.
We hypothesized that, a reduction in atherogenic malondiadehyde-modified low-density lipoprotein (MOA-LDL) levels, which may antagonize the action of athero-protective high-density lipoprotein cholesterol, leads to coronary plaque regression. This study investigated the effects of pravastatin on the serum levels of MDA-LDL and coronary atherosclerosis. In a 6-month prospective study, 75 patients with stable coronary artery disease were randomly assigned to a pravastatin-treatment group (n = 52) or a control group (n = 13). Volumetric analyses were performed in matched coronary artery segments by 3-dimensional intravascular ultrasound. Pravastatin therapy for 6 months resulted in a decrease in coronary plaque volume (14.4%, p < 0.0001) and a corresponding reduction in serum MDA-LDL levels (12.7%, p 0.0001). In the pravastatin treatment group, the percentage of change in plaque volume correlated with changes in the MDA-LDL and high-density lipoprotein cholesterol levels (r = 0.52 and -0.55, respectively, p < 0.0001) but not with the changes in any other lipid levels. Multivariate regression analysis revealed that a reduced MDA-LDL level is an independent predictor of plaque regression, as was an increase in high-density lipoprotein cholesterol. In conclusion, these results suggest that the reduction in the MDA-LDL levels induced by pravastatin may serve as A novel marker of coronary atherosclerosis regression. (c) 2005 Elsevier Inc. All rights reserved.